Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy
Jia-Yan Ni,1–3 Hong-Liang Sun,1,2 Jiang-Hong Luo,1,2 Xiong-Ying Jiang,1,2 Dong Chen,1,2 Wei-Dong Wang,1,2 Yao-Ting Chen,1,2 Jin-Hua Huang,3 Lin-Feng Xu1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Uni...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-11-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/transarterial-chemoembolization-and-sorafenib-combined-with-microwave--peer-reviewed-article-CMAR |
| _version_ | 1798044350241832960 |
|---|---|
| author | Ni JY Sun HL Luo JH Jiang XY Chen D Wang WD Chen YT Huang JH Xu LF |
| author_facet | Ni JY Sun HL Luo JH Jiang XY Chen D Wang WD Chen YT Huang JH Xu LF |
| author_sort | Ni JY |
| collection | DOAJ |
| description | Jia-Yan Ni,1–3 Hong-Liang Sun,1,2 Jiang-Hong Luo,1,2 Xiong-Ying Jiang,1,2 Dong Chen,1,2 Wei-Dong Wang,1,2 Yao-Ting Chen,1,2 Jin-Hua Huang,3 Lin-Feng Xu1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province 510120, People’s Republic of China; 2Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province 510120, People’s Republic of China; 3Department of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, Guangzhou, Guangdong Province 510060, People’s Republic of ChinaCorrespondence: Jin-Hua HuangDepartment of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong Province 510060, People’s Republic of ChinaTel +86-20-87343447Email huangjh_sysucc@163.comLin-Feng XuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang Road West, Guangzhou, Guangdong Province 510120, People’s Republic of ChinaTel +86-20-34078680Email xu_lin_feng@163.comPurpose: The aim of this study was to investigate the safety and efficacy of transarterial chemoembolization and sorafenib (TACE-S) combined with microwave ablation (TACE-S-MWA) for the treatment of patients with advanced primary hepatocellular carcinoma (HCC).Methods: Between January 2015 and December 2018, 152 consecutive advanced HCC patients, who underwent TACE-S-MWA (MWA group, n=77) or TACE-S (Non-MWA group, n=75), were investigated. Overall survival (OS), time to progression (TTP) and safety were compared between the two groups. Prognostic factors were analyzed using the Cox proportional hazard regression model.Results: Baseline patient characteristics were balanced between the two groups. MWA group was associated with a higher OS (median, 19.0 vs 13.0 months; P<0.001) and a longer TTP (median, 6.0 vs 3.0 months; P<0.001) compared with non-MWA group. Multivariate analyses showed that portal vein tumor thrombosis (PVTT) (P=0.002), duration of sorafenib (P<0.001), and MWA treatment (P=0.011) were independently associated with OS. MWA treatment strategy (P<0.001) was a significant predictor of TTP. There were no treatment-related mortalities in either group. The rates of minor complications (42.9% vs 38.7%, P=0.599) and major complications (1.29% vs 1.33%, P=0.985) in the MWA group were similar to those in the non-MWA group.Conclusion: TACE-S-MWA was safe and effective for advanced primary HCC. TACE-S-MWA resulted in better OS and TTP than did TACE-S for treatment of patients with advanced primary HCC.Keywords: hepatocellular carcinoma, transarterial chemoembolization, microwave ablation, sorafenib, survival |
| first_indexed | 2024-04-11T23:02:26Z |
| format | Article |
| id | doaj.art-1da635db75da4ea987ccf63df5792a0d |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-11T23:02:26Z |
| publishDate | 2019-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-1da635db75da4ea987ccf63df5792a0d2022-12-22T03:58:05ZengDove Medical PressCancer Management and Research1179-13222019-11-01Volume 119939995049983Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and EfficacyNi JYSun HLLuo JHJiang XYChen DWang WDChen YTHuang JHXu LFJia-Yan Ni,1–3 Hong-Liang Sun,1,2 Jiang-Hong Luo,1,2 Xiong-Ying Jiang,1,2 Dong Chen,1,2 Wei-Dong Wang,1,2 Yao-Ting Chen,1,2 Jin-Hua Huang,3 Lin-Feng Xu1,2 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province 510120, People’s Republic of China; 2Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province 510120, People’s Republic of China; 3Department of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, Guangzhou, Guangdong Province 510060, People’s Republic of ChinaCorrespondence: Jin-Hua HuangDepartment of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong Province 510060, People’s Republic of ChinaTel +86-20-87343447Email huangjh_sysucc@163.comLin-Feng XuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang Road West, Guangzhou, Guangdong Province 510120, People’s Republic of ChinaTel +86-20-34078680Email xu_lin_feng@163.comPurpose: The aim of this study was to investigate the safety and efficacy of transarterial chemoembolization and sorafenib (TACE-S) combined with microwave ablation (TACE-S-MWA) for the treatment of patients with advanced primary hepatocellular carcinoma (HCC).Methods: Between January 2015 and December 2018, 152 consecutive advanced HCC patients, who underwent TACE-S-MWA (MWA group, n=77) or TACE-S (Non-MWA group, n=75), were investigated. Overall survival (OS), time to progression (TTP) and safety were compared between the two groups. Prognostic factors were analyzed using the Cox proportional hazard regression model.Results: Baseline patient characteristics were balanced between the two groups. MWA group was associated with a higher OS (median, 19.0 vs 13.0 months; P<0.001) and a longer TTP (median, 6.0 vs 3.0 months; P<0.001) compared with non-MWA group. Multivariate analyses showed that portal vein tumor thrombosis (PVTT) (P=0.002), duration of sorafenib (P<0.001), and MWA treatment (P=0.011) were independently associated with OS. MWA treatment strategy (P<0.001) was a significant predictor of TTP. There were no treatment-related mortalities in either group. The rates of minor complications (42.9% vs 38.7%, P=0.599) and major complications (1.29% vs 1.33%, P=0.985) in the MWA group were similar to those in the non-MWA group.Conclusion: TACE-S-MWA was safe and effective for advanced primary HCC. TACE-S-MWA resulted in better OS and TTP than did TACE-S for treatment of patients with advanced primary HCC.Keywords: hepatocellular carcinoma, transarterial chemoembolization, microwave ablation, sorafenib, survivalhttps://www.dovepress.com/transarterial-chemoembolization-and-sorafenib-combined-with-microwave--peer-reviewed-article-CMARhepatocellular carcinomatransarterial chemoembolizationmicrowave ablationsorafenibsurvival |
| spellingShingle | Ni JY Sun HL Luo JH Jiang XY Chen D Wang WD Chen YT Huang JH Xu LF Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy Cancer Management and Research hepatocellular carcinoma transarterial chemoembolization microwave ablation sorafenib survival |
| title | Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy |
| title_full | Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy |
| title_fullStr | Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy |
| title_full_unstemmed | Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy |
| title_short | Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy |
| title_sort | transarterial chemoembolization and sorafenib combined with microwave ablation for advanced primary hepatocellular carcinoma a preliminary investigation of safety and efficacy |
| topic | hepatocellular carcinoma transarterial chemoembolization microwave ablation sorafenib survival |
| url | https://www.dovepress.com/transarterial-chemoembolization-and-sorafenib-combined-with-microwave--peer-reviewed-article-CMAR |
| work_keys_str_mv | AT nijy transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT sunhl transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT luojh transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT jiangxy transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT chend transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT wangwd transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT chenyt transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT huangjh transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy AT xulf transarterialchemoembolizationandsorafenibcombinedwithmicrowaveablationforadvancedprimaryhepatocellularcarcinomaapreliminaryinvestigationofsafetyandefficacy |